The Issuance Machine: Q3 Opens With a Record Pipeline, a Semiconductor Megadeal, and a Buyback Backstop

The headline: a record that is real, and also distorted

Through June 26, 2026, U.S. issuers raised $251 billion in IPO proceeds — the largest first-half total on record, surpassing the 2021 listing boom at the same point in the calendar.{{cite:chatcmpltool}} Renaissance Capital’s Q2 2026 review counted 48 IPOs pricing in the quarter alone, raising $104.9 billion, the largest single-quarter total since 2021.{{cite:chatcmpltool}}

The number is genuine. It is also heavily concentrated. SpaceX’s June 12 Nasdaq listing raised $75 billion and commanded a $1.7 trillion market cap at debut, making it instantly one of the largest public companies in the country.{{cite:chatcmpltool}} Alphabet’s $85 billion follow-on equity raise to fund AI infrastructure spending accounts for the other anchor.{{cite:chatcmpltool}} Together, those two transactions represent roughly 68% of the half-year total. Strip them out and the remaining issuance — 11 deals above $1 billion, led by AI chipmaker Cerebras Systems’ roughly $3.5 billion offering on May 14 — still marks the strongest non-mega-deal first half since 2021, but it reframes the story from “record” to “healthy recovery.”{{cite:chatcmpltool}}

The 60/40 call here is straightforward: I put roughly 60% odds on 2026 setting a full-year IPO proceeds record, and 40% on H2 cooling enough to leave the year impressive but short of the all-time high. The 40% case requires either an AI capex disappointment that re-rates the mega-cap cohort, a credit event that tightens financial conditions, or midterm-election volatility compressing the Q3 calendar into July and early August before the window narrows. Morgan Stanley has already flagged that Q3 deals are likely to be front-loaded for exactly that reason.{{cite:chatcmpltool}}

Q3 opens: Bending Spoons, SK hynix, and a thinning calendar

The first full trading week of July is lighter on headline deals than the Q2 barrage, but it carries two distinct signals.

Bending Spoons (BSP) priced its IPO on June 30 at $29 per share, above the marketed $26–$28 range, raising $1.68 billion via 57.97 million shares — 41% of which were sold by existing shareholders, including Baillie Gifford.{{cite:chatcmpltool}} The Milan-based software acquirer, whose portfolio includes Evernote, WeTransfer, Vimeo, and AOL, closed its first session at $40.50, up nearly 40%, for a market capitalization of approximately $25.7 billion.{{cite:chatcmpltool}} The deal is notable for two reasons beyond the pop: it defied a broader SaaS sector that has been under pressure from AI-displacement fears, and it carried a meaningful secondary component, signaling that existing backers wanted liquidity at the window — not just growth capital.

SK hynix (SKHY) is set to list American Depositary Receipts on Nasdaq on July 10, raising up to 45.45 trillion won (approximately $29.4 billion) in what would rank among the largest share sales in history.{{cite:chatcmpltool}} The world’s second-largest memory chipmaker plans to use all proceeds for capacity expansion, including construction of the Yongin semiconductor cluster in South Korea.{{cite:chatcmpltool}} A syndicate of BofA Securities, Citigroup, Goldman Sachs, and JPMorgan is managing the offering.{{cite:chatcmpltool}}

The deal is not technically an IPO — SK hynix is already listed on the Korea Exchange — but the ADR listing brings fresh primary issuance to U.S. markets and expands the investable float for American allocators. It also deepens the AI-infrastructure capital theme that has defined 2026 issuance: memory, accelerators, data centers, and satellite broadband are the verticals absorbing the largest pools of new equity.

The surrounding calendar is modest. IPOScoop lists Coolbit Technologies, MetaOptics (an uplisting), and Riku Dining Group for the week of July 6, with Tarsier Pharma on July 9.{{cite:chatcmpltool}} Two SPACs — Meridian3 Industrials Acquisition and Viking Acquisition Corp. II — priced on July 2.{{cite:chatcmpltool}} The relative thinness is consistent with a post-holiday week, but it also reflects the front-loading dynamic: bankers are accelerating deals that can price now rather than risking a late-Q3 window.

The buyback backstop: why gross issuance is not the same as net supply

The most common investor concern in this cycle is that record issuance will overwhelm the market. Goldman Sachs Research forecasts roughly $700 billion in combined IPO and follow-on supply for 2026 — but frames it as about 1% of total U.S. equity market capitalization, which is actually below the long-term average and roughly in line with the 2015–2019 environment.{{cite:chatcmpltool}}

The more important number is net supply. Goldman Sachs expects corporate buybacks to exceed $1 trillion in 2026, meaning corporate demand for shares will outweigh corporate supply even before accounting for retail, mutual fund, or hedge fund buyers.{{cite:chatcmpltool}} UBS reaches a similar conclusion from a different angle: IPO issuance of $200–350 billion, secondary offerings potentially exceeding $400 billion, and buybacks running at $1.2 trillion over the trailing twelve months. In aggregate, the corporate sector will likely buy back slightly more stock than it issues this year.{{cite:chatcmpltool}}

The bank stress tests provided a fresh injection of buyback capacity. On June 24, JPMorgan Chase unveiled a new $50 billion repurchase program effective July 1 and raised its quarterly dividend 10% to $1.65.{{cite:chatcmpltool}} Morgan Stanley reauthorized a $20 billion buyback and boosted its dividend 15% to $1.15. Goldman Sachs raised its payout 11% to $5, and Wells Fargo guided to an 11% dividend increase to $0.50.{{cite:chatcmpltool}} All 32 large banks passed the Fed’s annual stress test, and with stress capital buffers frozen through 2027 while the Fed overhauls its methodology, banks entered the announcements with clear visibility on their capital requirements.{{cite:chatcmpltool}}

The net-supply checklist

The math gets harder in 2027. Goldman Sachs’ Ben Snider notes that many 2026 IPOs are coming public with relatively small floats, which keeps immediate supply contained. But as lockups expire and more shares enter the market, the net-supply equation could tip.{{cite:chatcmpltool}} That is the structural risk to monitor — not this year, but next.

Lockup architecture: the quiet supply calendar

The standard 180-day lockup is a simplification. The 2026 mega-deals have adopted staged release structures that create multiple dates when new supply enters the market, and these dates are now embedded in the supply outlook for late 2026 and 2027.

SpaceX uses a phased approach. Elon Musk and certain significant investors face a 366-day lockup. Other pre-IPO employees and general investors may sell up to 20% of eligible shares after SpaceX reports its first quarterly results as a public company, with an additional 10% unlocked if the stock trades at least 30% above the IPO price during five of ten consecutive trading days before that earnings release. Further staggered releases follow subsequent quarterly reports.{{cite:chatcmpltool}}

Cerebras employs a more granular structure. Non-executive employees could sell 7.5% of eligible shares on the first trading day, and another 7.5% on day two — triggered because the stock closed more than 33% above its $185 IPO price on its first session. Directors, officers, and pre-IPO investors face a longer timeline: 15% of shares unlock after the company reports Q1 2026 earnings, with additional releases after Q2 earnings and on fixed dates in August, September, and October. A final portion remains locked until the earlier of the Q3 earnings release or the 180-day outside date.{{cite:chatcmpltool}}

Both companies bar hedging, short sales, swaps, and other synthetic arrangements that would let holders work around the lockup economically.{{cite:chatcmpltool}}

The practical implication: the aftermarket volatility that followed SpaceX’s debut — the stock shed roughly $400 billion in market capitalization over a four-session stretch in late June, including a single-day decline of about 16%{{cite:chatcmpltool}} — may be a preview of the price action around staged unlock dates, not just a function of initial supply-demand imbalance.

Follow-ons and secondaries: the quieter channel

Secondary offerings are running at a pace that could exceed $400 billion for the year, per UBS estimates.{{cite:chatcmpltool}} The deals span sectors but share a theme: companies with existing public floats tapping demand while the window is open.

Abivax priced an upsized $800 million public offering of American Depositary Shares on July 1, increased from an initially planned $600 million, at $125 per ADS. The offering was described as highly oversubscribed, with underwriters holding a 15% overallotment option.{{cite:chatcmpltool}} The French clinical-stage biotechnology company is using proceeds to advance obefazimod development in chronic inflammatory diseases.{{cite:chatcmpltool}}

The Abivax deal illustrates a pattern worth tracking: oversubscription levels and upsize frequency are real-time indicators of demand depth. When coverage ratios begin to drop or deals start pricing within — rather than above — their ranges, it is an early signal that the market’s capacity for new paper is being absorbed faster than issuers can supply it.

Exchange-level plumbing: NYSE American tightens

Away from the headline deals, a structural change in listing standards took effect this spring. NYSE American materially tightened its initial listing requirements following SEC approval of amendments published in the April 1, 2026 Federal Register notice.{{cite:chatcmpltool}}

The key changes:

• Minimum share price raised to $4.00, replacing the previous $2.00 and $3.00 thresholds, aligning NYSE American with Nasdaq and other major exchanges.{{cite:chatcmpltool}}
• Standard 1 unrestricted public float increased to $15 million from $3 million, with the calculation now limited to unrestricted publicly held shares — excluding Reg D private placements, Reg S securities, lock-up shares, and Rule 144 restricted securities.{{cite:chatcmpltool}}
• IPO float must come from the offering itself: at least $15 million in unrestricted public float must be derived solely from offering proceeds. Pre-existing shareholders can no longer be relied upon to satisfy the requirement.{{cite:chatcmpltool}}
• Stockholders’ equity under Standard 2 increased from $4 million to $5 million, and certain uplisting applicants must satisfy market cap and price requirements over 90 consecutive trading days.{{cite:chatcmpltool}}

The changes move NYSE American closer to Nasdaq’s standards and are expected to have the greatest impact on early-stage microcap issuers and companies with concentrated or restricted ownership — particularly Canadian companies that have historically used NYSE American as a cross-border listing venue.{{cite:chatcmpltool}} In practical terms, exchange selection decisions are being made earlier in the IPO process, and offering size and structure now play a more direct role in determining listing viability.

Global context: concentration risk in one chart’s worth of words

Global ECM volumes reached $729.4 billion in the first half of 2026, a 73.1% increase over 1H25 and the second-best start to a year on record, behind only 1H21.{{cite:chatcmpltool}} Technology deals accounted for roughly 30% of total deal flow; including SpaceX — classified as aerospace under Dealogic methodology but carrying a substantial AI component in its equity story — that figure rises to 41.4%.{{cite:chatcmpltool}}

That concentration is the central risk. Whether markets can sustain issuance at this pace from a single sector, anchored to the sole theme of AI growth, is the question on which the next few quarters of ECM activity are likely to hinge.{{cite:chatcmpltool}} Goldman Sachs’ IPO Barometer — combining interest rates, CEO confidence, and equity valuations — currently reads 140 against a long-term average of 100, near the top of its historical range but below 2021 peaks.{{cite:chatcmpltool}} If AI momentum deteriorates, those indicators would likely deteriorate with it.

What to watch next

1. SK hynix ADR pricing and first-day performance (July 10). At roughly $29 billion, this is the largest Q3 deal by a wide margin. Demand depth and aftermarket behavior will signal whether the AI-infrastructure capital theme extends beyond U.S.-domiciled issuers to international mega-caps tapping U.S. pools.

2. SpaceX staged lockup releases. The first quarterly earnings report as a public company will trigger up to 20% of eligible shares for non-Musk holders, with a potential additional 10% if the price condition is met.{{cite:chatcmpltool}} The stock’s late-June volatility — a ~$400 billion market-cap drawdown over four sessions{{cite:chatcmpltool}} — makes the unlock dates a concrete supply event to monitor.

3. Cerebras staged unlocks through October. Employee shares already partially released; director/officer and pre-IPO investor tranches unlock after Q1 and Q2 earnings reports and on fixed August–October dates.{{cite:chatcmpltool}} Each release is a localized supply test.

4. Follow-on oversubscription and upsize frequency. When deals stop being upsized or begin pricing within their ranges — rather than above — it marks the leading edge of demand absorption. Abivax’s upsized, oversubscribed $800 million offering is the current benchmark.{{cite:chatcmpltool}}

5. Q3 calendar pacing and midterm-election compression. Morgan Stanley expects front-loading.{{cite:chatcmpltool}} If the August–September calendar thins sharply, it will confirm that issuers are pricing political risk into their timing decisions and that H2 supply may fall short of the pace needed for a full-year record.

6. Net equity supply inflection in 2027. Buybacks exceed issuance in 2026, but Goldman Sachs flags that the math gets harder next year as lockup expirations release more shares and small-float IPOs gradually expand their public float.{{cite:chatcmpltool}} The transition from net shrinkage to net expansion — if it arrives — would be the most consequential market-structure shift since the post-2021 issuance drought began.

FN2 Research provides financial research and education, not personalized investment advice. This article is based on publicly available sources cited inline and does not constitute a recommendation to buy, sell, or hold any security.